1. Home
  2. TRVI vs BGM Comparison

TRVI vs BGM Comparison

Compare TRVI & BGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • BGM
  • Stock Information
  • Founded
  • TRVI 2011
  • BGM 2019
  • Country
  • TRVI United States
  • BGM China
  • Employees
  • TRVI N/A
  • BGM N/A
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • BGM
  • Sector
  • TRVI Health Care
  • BGM
  • Exchange
  • TRVI Nasdaq
  • BGM NYSE
  • Market Cap
  • TRVI 341.4M
  • BGM 894.4M
  • IPO Year
  • TRVI 2019
  • BGM 2021
  • Fundamental
  • Price
  • TRVI $4.24
  • BGM $9.90
  • Analyst Decision
  • TRVI Strong Buy
  • BGM
  • Analyst Count
  • TRVI 8
  • BGM 0
  • Target Price
  • TRVI $9.31
  • BGM N/A
  • AVG Volume (30 Days)
  • TRVI 454.6K
  • BGM 61.3K
  • Earning Date
  • TRVI 03-19-2025
  • BGM 02-13-2025
  • Dividend Yield
  • TRVI N/A
  • BGM N/A
  • EPS Growth
  • TRVI N/A
  • BGM N/A
  • EPS
  • TRVI N/A
  • BGM N/A
  • Revenue
  • TRVI N/A
  • BGM N/A
  • Revenue This Year
  • TRVI N/A
  • BGM N/A
  • Revenue Next Year
  • TRVI N/A
  • BGM N/A
  • P/E Ratio
  • TRVI N/A
  • BGM N/A
  • Revenue Growth
  • TRVI N/A
  • BGM N/A
  • 52 Week Low
  • TRVI $1.39
  • BGM $1.78
  • 52 Week High
  • TRVI $4.68
  • BGM $14.78
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 60.00
  • BGM 52.04
  • Support Level
  • TRVI $3.81
  • BGM $9.00
  • Resistance Level
  • TRVI $4.04
  • BGM $11.00
  • Average True Range (ATR)
  • TRVI 0.25
  • BGM 1.15
  • MACD
  • TRVI -0.00
  • BGM -0.13
  • Stochastic Oscillator
  • TRVI 90.89
  • BGM 47.78

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About BGM QILIAN INTERNATIONAL HLDG GROUP LTD

BGM Group Ltd formerly, Qilian International Holding Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.

Share on Social Networks: